Below are your results for the search term: parkinson*

Search Again    Back to previous page

• 1. Pergolide mesylate can improve sexual dysfunction in patients with Parkinson's disease: the results of an open, prospective, 6-month follow-up.
• 2. Atypical antipsychotic profile of flunarizine in animal models.
• 3. Treatment with alpha2-adrenoceptor antagonist, 2-methoxy idazoxan, protects 6-hydroxydopamine-induced Parkinsonian symptoms in rats: neurochemical and behavioral evidence.
• 4. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
• 5. A synthetic retinoid Am80 (tamibarotene) rescues the memory deficit caused by scopolamine in a passive avoidance paradigm.
• 6. Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease.
• 7. Levodopa and the progression of Parkinson's disease.
• 8. Rivastigmine for dementia associated with Parkinson's disease.
• 9. 3-hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity.
• 10. Cognitive performance in people with Parkinson's disease and mild or moderate depression: effects of dopamine agonists in an add-on to L-dopa therapy.
• 11. Thrombin preconditioning provides protection in a 6-hydroxydopamine Parkinson's disease model.
• 12. A synthetic derivative of the natural product rocaglaol is a potent inhibitor of cytokine-mediated signaling and shows neuroprotective activity in vitro and in animal models of Parkinson's disease and traumatic brain injury.
• 13. KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse.
• 14. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
• 15. Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice.
• 16. Femtomolar concentrations of dextromethorphan protect mesencephalic dopaminergic neurons from inflammatory damage.
• 17. Microglial NADPH oxidase is a novel target for femtomolar neuroprotection against oxidative stress.
• 18. Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation.
• 19. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.
• 20. Pharmacological study of the novel compound FLZ against experimental Parkinson's models and its active mechanism.
• 21. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study.
• 22. Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease.
• 23. Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease.
• 24. Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease.
• 25. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury.
• 26. Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function.
• 27. Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice.
• 28. Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 1: eradication of Helicobacter in the cachexia of idiopathic parkinsonism.
• 29. Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 2: response of facets of clinical idiopathic parkinsonism to Helicobacter pylori eradication. A randomized, double-blind, placebo-controlled efficacy study.
• 30. Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 3: predicted probability and gradients of severity of idiopathic parkinsonism based on H. pylori antibody profile.
• 31. K-ATP channels promote the differential degeneration of dopaminergic midbrain neurons.
• 32. Lentivector-mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model.
• 33. Regulation of p53 by activated protein kinase C-delta during nitric oxide-induced dopaminergic cell death.
• 34. An open-label extension trial of risperidone monotherapy in the treatment of bipolar I disorder.
• 35. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.
• 36. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.
• 37. Anti-Parkinsonian agents have anti-amyloidogenic activity for Alzheimer's beta-amyloid fibrils in vitro.
• 38. BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD Study.
• 39. The effect of epigallocatechin gallate on suppressing disease progression of ALS model mice.
• 40. Low molecular weight thiol amides attenuate MAPK activity and protect primary neurons from Abeta(1-42) toxicity.
• 41. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.
• 42. Prevalence of bladder dysfunction in Parkinsons disease.
• 43. Central acute D2 stimulation worsens bladder function in patients with mild Parkinson's disease.
• 44. Identification of a pharmacophore of SKCa channel blockers.
• 45. Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models.
• 46. Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials.
• 47. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease.
• 48. Design, synthesis, and biological activity of novel polycyclic aza-amide FKBP12 ligands.
• 49. Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model.
• 50. Synthesis of novel benzofuran isoxazolines as protein tyrosine phosphatase 1B inhibitors.

1 - 50 results more>>